U.S. markets open in 8 hours 7 minutes

Bionomics Limited (BNOEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1563-0.0007 (-0.45%)
At close: 3:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1570
BidN/A x N/A
AskN/A x N/A
Day's Range0.1550 - 0.1631
52 Week Range0.0340 - 0.3500
Avg. Volume264,316
Market Cap161.942M
Beta (5Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bionomics BNC210 Expansion into Social Anxiety Disorder
    PR Newswire

    Bionomics BNC210 Expansion into Social Anxiety Disorder

    Bionomics Limited (OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder (PTSD) in the middle of this year.


    Novamind Increases Strategic Investment in Bionomics

    Investment supports phase IIb clinical trial examining novel PTSD treatmentTORONTO, ON / ACCESSWIRE / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has increased its strategic investment in Bionomics Limited ("Bionomics") (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

  • Bionomics Successfully Completes A$22.9 million Equity Raise
    PR Newswire

    Bionomics Successfully Completes A$22.9 million Equity Raise

    Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurrent placement that was announced on 17 March 2021 (Concurrent Placement) which collectively raised approximately A$22.9 million.